OTO-413
Drug
Otonomy, Inc.
Total Payments
$348,191
Transactions
24
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $348,191 | 24 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $328,503 | 17 | 94.3% |
| Consulting Fee | $19,688 | 7 | 5.7% |
Payments by Type
Research
$328,503
17 transactions
General
$19,688
7 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single intratymoanic injection in subjects with speech-in-noise hearing impairment | Otonomy, Inc. | $291,940 | 0 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single Intratympanic injection in subjects with speech-in-noise hearing impairment | Otonomy, Inc. | $36,563 | 0 |
Top Doctors Receiving Payments for OTO-413
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $328,503 | 17 |
| Stephen Bradley | — | La Jolla, CA | $17,675 | 5 |
| , MD | Otolaryngology | St Louis, MO | $2,013 | 2 |
Ad
Manufacturing Companies
- Otonomy, Inc. $348,191
Product Information
- Type Drug
- Total Payments $348,191
- Total Doctors 2
- Transactions 24
About OTO-413
OTO-413 is a drug associated with $348,191 in payments to 2 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Otonomy, Inc..
Payment data is available from 2020 to 2020. In 2020, $348,191 was paid across 24 transactions to 2 doctors.
The most common payment nature for OTO-413 is "Unspecified" ($328,503, 94.3% of total).
OTO-413 is associated with 2 research studies, including "A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single intratymoanic injection in subjects with speech-in-noise hearing impairment" ($291,940).